Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prader-Willi region non-protein coding RNA 2 (PWRN2)
- Target
- PWRN2
- Molecular classification
- Long non-coding RNA (lncRNA), Other (Non-protein coding RNA)
01
Overview
Prader-Willi region non-protein coding RNA 2 (PWRN2) is a long non-coding RNA transcribed from the Prader-Willi locus on chromosome 15. It does not encode a protein but rather modulates gene expression via several mechanisms, most notably as a competing endogenous RNA. It has roles in neurodevelopment (regulation of neurodevelopmental gene transcription), in the cellular response to stress (promoting cell death and apoptosis in retinal cells exposed to oxidative injury), and in female reproductive biology (affecting oocyte maturation and metabolic gene regulation in PCOS). PWRN2’s dysregulation has been associated with pathologies such as Prader-Willi syndrome, age-related macular degeneration, and polycystic ovary syndrome. Currently, no drugs target PWRN2 directly, but its expression may serve as a disease biomarker or as a molecular node for future therapeutic RNA interventions[1][2][3][7][8].
- Other names
- NCRNA00199non-protein coding RNA 199PWRN2
02
Mechanism of action
No drugs act directly on PWRN2. Its mechanism includes ceRNA function—regulating miRNA availability and thus downstream mRNA translation
03
Biological functions
Regulation of gene expression, especially neurodevelopmental genesRegulation of cell death and apoptosis (under stress conditions)Cell cycle regulation in specific contexts (e.g., oocyte maturation and metabolic processes in PCOS)Competing endogenous RNA (ceRNA) activity—modulates microRNA networks, alters gene expression via miRNA sponging
04
Disease associations
Prader-Willi syndrome (structural genomic context, likely contributing to pathogenesis)Age-related macular degeneration (AMD, involved in cell death and apoptosis of retinal pigment epithelial cells)Polycystic ovary syndrome (PCOS, roles in oocyte maturation and metabolic dysfunction)Neurodevelopmental disorders (potential regulatory role in gene expression during neuronal development)
05
Safety considerations
No known safety or therapeutic risks directly associated with targeting or manipulating PWRN2, though its involvement in disease-related cellular processes could pose challenges in gene therapy or RNA-targeted strategies
06
Biomarkers
Potential biomarker for disease states where its expression is altered: Age-related macular degeneration—expression upregulated in damaged retinal cellsPotential biomarker for disease states where its expression is altered: PCOS—expression upregulated in cumulus cells in affected patients
Beyond the preview
Go deeper on Prader-Willi region non-protein coding RNA 2 (PWRN2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prader-Willi region non-protein coding RNA 2 (PWRN2).